Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
April 27 2010 - 10:45AM
PR Newswire (US)
QUEBEC CITY, April 27 /PRNewswire-FirstCall/ - Aeterna
Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a
late-stage drug development company specialized in oncology and
endocrinology, announced today that it has received a letter from
the Nasdaq Stock Market notifying it that the closing price per
share of the Company's common stock was above the US$1.00 minimum bid price for 10 consecutive
trading days and that, as a result, the Company has regained
compliance with Marketplace Rule 5450(a)(1) (the minimum bid price
rule) as of Friday, April 23,
2010.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company
specialized in oncology and endocrine therapy News releases and
additional information are available at www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.
Copyright l 27 PR Newswire
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024